|1.||Schwartsmann, Gilberto: 14 articles (01/2015 - 01/2006)|
|2.||Roesler, Rafael: 13 articles (06/2013 - 01/2006)|
|3.||Dal-Pizzol, Felipe: 8 articles (06/2013 - 01/2006)|
|4.||Petronilho, Fabricia: 5 articles (06/2013 - 08/2009)|
|5.||Schally, Andrew V: 4 articles (01/2012 - 03/2002)|
|6.||Streck, Emilio L: 4 articles (03/2011 - 08/2009)|
|7.||Schally, A V: 4 articles (01/2004 - 03/2000)|
|8.||Ritter, Cristiane: 3 articles (01/2012 - 01/2006)|
|9.||Schwartsmann, G: 3 articles (10/2011 - 09/2006)|
|10.||Rezin, Gislaine T: 3 articles (03/2011 - 08/2009)|
01/01/2006 - "The administration of RC-3095 (0.3 mg/kg) 6 h after sepsis induction improved survival in the CLP model, and diminished lung damage after intratracheal instillation of LPS. "
01/10/2012 - "RC-3095 is a selective GRPR antagonist, recently found to have antiinflammatory properties in arthritis and sepsis models. "
01/01/2012 - "Human patients with a clinical diagnosis of sepsis received a continuous infusion with RC-3095 (3 mg/kg, intravenous) over a period of 12 h, and plasma was collected before and after RC-3095 administration and, in a different set of patients with systemic inflammatory response syndrome (SIRS) or sepsis, GRP plasma levels were determined. "
01/01/2006 - "We determined the effects of RC-3095 in the CLP model of sepsis and in acute lung injury induced by intratracheal instillation of LPS. "
01/01/2006 - "To determine the effects of a selective GRP receptor antagonist, RC-3095, on cytokine release from macrophages and its in vivo effects in the cecal ligation and puncture (CLP) model of sepsis and in acute lung injury induced by intratracheal instillation of LPS. "
09/01/2006 - "Considering the novelty of its mechanism of action and impressive preclinical anti-tumor activity, further studies exploiting new formulations of RC-3095 for human use, such as slow-release preparations, and analogues with a more favorable pharmacokinetics are warranted."
06/01/2009 - "In in vivo experiments, the control group displayed the largest tumors (52 +/- 15.5 mm(3)), whereas RC-3095 reduced the tumor size, with the most significant effect at the dose of 0.3 mg/kg (21 +/- 9.7 mm(3)). "
08/18/2007 - "RC-3095, a BBS/GRP antagonist, attenuated BBS-stimulated tumor growth and angiogenesis in vivo. "
09/01/2006 - "The novel BN/GRP synthetic receptor antagonist, RC-3095, was able to produce long-lasting tumor regressions in murine and human tumor models in vitro and in vivo. "
10/09/1995 - "Treatment with RC-3095 induced smaller, and not significant, decreases in tumor volume and weight. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
05/08/1993 - "The number of animals with pancreatic cancers was significantly lower in the group treated with 60 micrograms/day of RC-3095 and the weight of tumorous pancreata was reduced. "
05/08/1993 - "RC-3095 exerted a dose-dependent inhibitory effect on growth of pancreatic cancers. "
01/01/2014 - "The antiproliferation effects of RC-3095, gemcitabine, or the combination on pancreatic cancer were monitored in vitro. "
11/01/1991 - "In view of its strong inhibitory effect on experimental pancreatic tumors, the bombesin antagonist RC-3095 might be considered as a possible new agent for the therapy of human exocrine pancreatic cancer."
01/01/2014 - "In this study, we investigated the efficacy of a combination of gastrin-releasing peptide receptor antagonist RC-3095 and gemcitabine on pancreatic cancer CFPAC-1. "
|4.||Prostatic Neoplasms (Prostate Cancer)
10/15/2010 - "These findings shed light on the mechanisms of action of these analogs and support the view that the use of AN-215 and RC-3095 for blocking BN/GRP receptors for targeted therapy may be of benefit for treatment of advanced prostate cancer."
01/01/1992 - "The finding that bombesin antagonist RC-3095 inhibits the growth of PC-82 prostate cancer suggests the merit of further studies to evaluate the possible usefulness of antagonists of bombesin in the management of prostatic carcinoma."
12/01/1993 - "Combination therapy of LH-RH analogs with bombesin antagonists such as RC-3095 might be considered for improvement of hormonal therapy of prostate cancer."
12/16/1992 - "We have recently shown that antagonists of bombesin and gastrin-releasing peptide, including RC-3095, inhibit the growth of pancreatic, colonic, and prostatic cancers in experimental animals. "
12/01/1993 - "The effects of treatment with bombesin/gastrin-releasing peptide (GRP) receptor antagonist [D-Tpi6, Leu13 psi(CH2NH)Leu14]BN(6-14)(RC-3095), an agonist of LH-RH [D-Lys6]-LH-RH and their combination were investigated in the androgen-dependent Dunning R-3327H rat prostate cancer model. "
01/01/2015 - "RC-3095, a selective GRPR antagonist, has been shown to have anti-inflammatory properties in different models of inflammation. "
10/01/2011 - "Synovial inflammation, synovial hyperplasia, pannus formation, and extensive erosive changes were all dramatically reduced in the arthritic mice treated with RC-3095. "
08/01/2010 - "RC-3095 was the only treatment to significantly reduce macroscopic and microscopic scores of inflammation as compared with the animals from the non-treated colitis group. "
09/01/2010 - "We report the effects of the gastrin-releasing peptide (GRP) receptor antagonist RC-3095 in an acute inflammation model induced by carrageenan. "
|2.||Bombesin Receptors (Bombesin Receptor)
|4.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|10.||Creatine Kinase (Creatine Phosphokinase)
|2.||Heterologous Transplantation (Xenotransplantation)